Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14.4B | $2.7B | $4.1B | $2.2B | 18.6% | 28.6% |
| 2025-12-31 | $17.6B | $-1.6B | $3.5B | $4.5B | -9.4% | 19.8% |
| 2025-09-30 | $16.7B | $3.5B | $4.1B | $4.0B | 21.3% | 24.8% |
| 2025-06-30 | $14.7B | $2.9B | $3.8B | $-1.2B | 19.9% | 25.7% |
| 2025-03-31 | $13.7B | $3.0B | $4.4B | $1.8B | 21.6% | 32.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
| 2024-09-30 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-05-05 | 0.75 | 0.72 | +3.9% |
| 2026-02-03 | 0.66 | 0.57 | +16.2% |
| 2025-11-04 | 0.87 | 0.63 | +37.4% |
| 2025-08-05 | 0.51 | 0.36 | +41.6% |
| 2025-04-29 | 0.92 | 0.67 | +36.5% |
| 2025-02-04 | 0.63 | 0.46 | +37.2% |
| 2024-10-29 | 1.06 | 0.61 | +73.3% |
| 2024-07-30 | 0.60 | 0.46 | +30.2% |
| 2024-05-01 | 0.82 | 0.51 | +60.1% |
| 2024-01-30 | 0.10 | -0.18 | +154.7% |
| 2023-10-31 | -0.42 | -0.50 | +16.8% |
| 2023-08-01 | 0.67 | 0.58 | +15.3% |
| 2023-05-02 | 1.23 | 0.99 | +24.7% |
| 2023-01-31 | 1.14 | 1.04 | +9.4% |
| 2022-11-01 | 1.78 | 1.40 | +27.0% |
| 2022-07-28 | 2.04 | 1.78 | +14.8% |
| 2022-05-03 | 1.62 | 1.57 | +3.5% |
| 2022-02-08 | 1.08 | 0.87 | +23.6% |
| 2021-11-02 | 1.34 | 1.09 | +23.5% |
| 2021-07-28 | 1.07 | 0.98 | +9.4% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $970B | 38.6 | 24.5 | 13.4 | 27.3 | 31.1 | 82.8% | 55.5% | 169.9% | 0.94% |
| UNH | $348B | 28.9 | 18.4 | 0.8 | 18.5 | 3.6 | 18.8% | 2.0% | 0.7% | 5.08% |
| JNJ | $540B | 26.0 | 17.6 | 5.6 | 16.6 | 6.7 | 68.0% | 9.9% | -52.9% | 2.32% |
| MRK | $286B | 32.6 | 12.1 | 4.4 | 11.2 | 6.2 | 76.7% | 4.9% | — | 4.91% |
| ABBV | $387B | 106.8 | 13.5 | 6.2 | 14.8 | -58.1 | 72.0% | 12.4% | -46.2% | 5.38% |
| PFE ★ | $145B | 19.4 | 9.0 | 2.3 | 7.8 | 1.6 | 74.8% | 5.4% | -10.1% | 8.52% |
| TMO | $175B | 26.0 | 17.3 | 3.9 | 19.4 | 3.3 | 40.9% | 6.2% | 11.3% | 3.15% |
| ABT | $152B | 24.4 | 14.4 | 3.4 | 15.2 | 2.9 | 56.5% | 7.8% | -19.7% | 4.18% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 31.42%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 498,257,550 | 8.74% |
| Vanguard Capital Management LLC | 369,430,012 | 6.48% |
| State Street Corporation | 301,589,865 | 5.29% |
| Geode Capital Management, LLC | 133,561,742 | 2.34% |
| Vanguard Portfolio Management LLC | 116,734,695 | 2.05% |
| Fisher Asset Management, LLC | 104,964,427 | 1.84% |
| Morgan Stanley | 92,685,370 | 1.63% |
| Northern Trust Corporation | 62,026,552 | 1.09% |
| Massachusetts Financial Services Co. | 56,911,830 | 1.00% |
| State Farm Mutual Automobile Insuran | 54,508,560 | 0.96% |
Insider activity · 90d
No insider trades for PFE in last 90d.
Analyst estimates
yfinanceConsensus: buy (mean 2.44828). Distribution requires FINNHUB_API_KEY.
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-01 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-18 | Insider transaction (Form 4) | view · |
| 13F-HR | 2026-05-12 | Institutional holdings (13F) | view · |
| 10-Q | 2026-05-05 | 10-Q | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| 4 | 2026-05-04 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 8-K | 2026-04-27 | 8-K | view · |
| 4 | 2026-04-17 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-16 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-01 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-16 | Insider transaction (Form 4) | view · |
| DEF 14A | 2026-03-12 | DEF 14A | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-03 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-27 | Insider transaction (Form 4) | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 4 | 2026-02-24 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-24 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-17 | Insider transaction (Form 4) | view · |
| 13F-HR | 2026-02-12 | Institutional holdings (13F) | view · |
| 8-K | 2026-02-03 | 8-K | view · |
| 4 | 2026-02-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-16 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-05 | Insider transaction (Form 4) | view · |
About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well a…